BR9714328A - da atividade de interleucina-1 - Google Patents
da atividade de interleucina-1Info
- Publication number
- BR9714328A BR9714328A BR9714328A BR9714328A BR9714328A BR 9714328 A BR9714328 A BR 9714328A BR 9714328 A BR9714328 A BR 9714328A BR 9714328 A BR9714328 A BR 9714328A BR 9714328 A BR9714328 A BR 9714328A
- Authority
- BR
- Brazil
- Prior art keywords
- acute
- salpingitis
- perma
- rro
- pericarditis
- Prior art date
Links
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 208000007893 Salpingitis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000003305 autocrine Effects 0.000 abstract 1
- 208000003167 cholangitis Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000011379 keloid formation Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000008494 pericarditis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
nforme anteriormente definidos, útil no tratamento de uma condição selecionada do grupo constituído por meningite e salpingite, choque séptico, coagulofrimento respiratório adulto, inflamação aguda ou crónica, artrite, colangite, colite, encefalite, e, pancreatite, pericardite, lesão de reperfusão, vasculite, hipersensibilidade aguda e retardada, rro, doenças auto-imunes que incluem diabetes mellitus do Tipo 1 e esclerose múltipla, doenças peridentais, fibrose pulmonar intersticial, cirrose, esclerose sistêmica, formação de quelóide, tumores que produzem IL-1 como fator de crescimento de autocrina, caquexia, doença de Alzheimer, lesão de percm mamífero, incluindo um humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3697997P | 1997-01-29 | 1997-01-29 | |
| PCT/IB1997/001603 WO1998032733A1 (en) | 1997-01-29 | 1997-12-29 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9714328A true BR9714328A (pt) | 2000-03-21 |
Family
ID=21891776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9714328A BR9714328A (pt) | 1997-01-29 | 1997-12-29 | da atividade de interleucina-1 |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6166064A (pt) |
| EP (1) | EP0964849B1 (pt) |
| JP (1) | JP3573757B2 (pt) |
| KR (1) | KR100324058B1 (pt) |
| CN (1) | CN1127479C (pt) |
| AP (1) | AP929A (pt) |
| AR (1) | AR011093A1 (pt) |
| AT (2) | ATE270285T1 (pt) |
| AU (1) | AU723895B2 (pt) |
| BG (1) | BG103597A (pt) |
| BR (1) | BR9714328A (pt) |
| CA (1) | CA2279186C (pt) |
| CO (1) | CO4920230A1 (pt) |
| CZ (1) | CZ293173B6 (pt) |
| DE (2) | DE69729762T2 (pt) |
| DK (2) | DK1270565T3 (pt) |
| DZ (1) | DZ2407A1 (pt) |
| EA (1) | EA001803B1 (pt) |
| ES (2) | ES2198598T3 (pt) |
| HR (1) | HRP980045B1 (pt) |
| HU (1) | HUP0000567A3 (pt) |
| ID (1) | ID22223A (pt) |
| IL (1) | IL130855A0 (pt) |
| IS (1) | IS5099A (pt) |
| MA (1) | MA26468A1 (pt) |
| NO (1) | NO313279B1 (pt) |
| NZ (1) | NZ336248A (pt) |
| OA (1) | OA11079A (pt) |
| PA (1) | PA8444701A1 (pt) |
| PE (1) | PE57898A1 (pt) |
| PL (1) | PL335052A1 (pt) |
| PT (2) | PT964849E (pt) |
| SK (1) | SK283679B6 (pt) |
| TN (1) | TNSN98017A1 (pt) |
| TR (1) | TR199901816T2 (pt) |
| TW (1) | TW515788B (pt) |
| UY (1) | UY24861A1 (pt) |
| WO (1) | WO1998032733A1 (pt) |
| YU (1) | YU33799A (pt) |
| ZA (1) | ZA98685B (pt) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022984A (en) * | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
| EP1526383A3 (en) * | 1998-08-31 | 2005-11-16 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| AU6464400A (en) * | 1999-09-14 | 2001-04-17 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| DE122010000047I1 (de) | 2001-06-26 | 2011-05-05 | Amgen Fremont Inc | Antikörper gegen opgl |
| CA2459454A1 (en) | 2001-09-14 | 2003-03-27 | Bayer Pharmaceuticals Corporation | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| MXPA04002565A (es) * | 2001-11-30 | 2004-05-31 | Pfizer Prod Inc | Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion. |
| US20030131370A1 (en) * | 2001-12-14 | 2003-07-10 | Pfizer Inc. | Disruption of the glutathione S-transferase-Omega-1 gene |
| JP2005538066A (ja) | 2002-07-09 | 2005-12-15 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物 |
| CN100471871C (zh) | 2002-09-06 | 2009-03-25 | 安姆根有限公司 | 治疗性人抗－il－1r1单克隆抗体 |
| WO2004031777A1 (en) * | 2002-10-03 | 2004-04-15 | Pfizer Products Inc. | Use of gst-omega-2 as a therapeutic target |
| NZ619746A (en) | 2003-08-06 | 2014-05-30 | Senomyx Inc | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
| PT1776336E (pt) * | 2004-03-23 | 2009-12-18 | Dompe Spa | Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm |
| US20060045953A1 (en) * | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| ES2776973T3 (es) | 2005-02-04 | 2020-08-03 | Firmenich Incorporated | Compuestos que comprenden restos de heteroarilo unidos y su uso como nuevos modificadores del sabor umami, saborizantes y potenciadores del sabor para composiciones comestibles |
| WO2006090921A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物のリンパ球活性化抑制作用 |
| US7208526B2 (en) * | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| TWI425917B (zh) | 2006-04-21 | 2014-02-11 | Senomyx Inc | 包含高度鮮味風味劑之可食用組合物及其製造方法 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| US7973051B2 (en) * | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
| EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
| CA2957566C (en) | 2014-08-12 | 2023-08-01 | Daniel Paul Becker | Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same |
| US10538487B2 (en) | 2015-02-16 | 2020-01-21 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| WO2016138473A1 (en) * | 2015-02-26 | 2016-09-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| WO2017140778A1 (en) | 2016-02-16 | 2017-08-24 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| EP3445749B1 (en) | 2016-04-18 | 2022-12-21 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3445757B1 (en) | 2016-04-18 | 2020-11-25 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| US20220267260A1 (en) * | 2016-11-29 | 2022-08-25 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
| EP3851434A1 (en) | 2017-01-23 | 2021-07-21 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| CA3059458A1 (en) * | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| AU2018297606B2 (en) | 2017-07-07 | 2022-08-11 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| CN117143042A (zh) | 2017-07-24 | 2023-12-01 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| SG11202001166RA (en) | 2017-08-15 | 2020-03-30 | Inflazome Ltd | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| ES2927851T3 (es) * | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| CN108299256B (zh) * | 2018-01-09 | 2019-09-10 | 武汉大学 | 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用 |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
| BR112021001012A2 (pt) | 2018-07-20 | 2021-04-20 | F. Hoffmann-La Roche Ag | compostos de sulfonilureia como inibidores da atividade de interleucina-1 |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2020086732A1 (en) | 2018-10-24 | 2020-04-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| AU2020210117A1 (en) | 2019-01-14 | 2021-08-05 | Zydus Lifesciences Limited | Novel substituted sulfonylurea derivatives |
| EP3986879A1 (en) | 2019-06-21 | 2022-04-27 | AC Immune SA | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| CN114746087A (zh) * | 2019-09-12 | 2022-07-12 | 载度思生命科学有限公司 | 新的经取代的亚砜亚胺衍生物 |
| US20230219920A1 (en) * | 2020-06-11 | 2023-07-13 | Medshine Discovery Inc. | Dimethylsulfoximine derivative |
| JP2023531008A (ja) | 2020-06-19 | 2023-07-20 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路を調節するジヒドロオキサゾール及びチオ尿素または尿素誘導体 |
| WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
| CN116783184A (zh) | 2020-09-04 | 2023-09-19 | 诺瑟拉有限公司 | 含有烷基-氧杂环烷基部分的氨磺酰基脲衍生物及其用途 |
| ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
| WO2023098612A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2023156311A1 (en) * | 2022-02-15 | 2023-08-24 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4586950A (en) * | 1982-05-31 | 1986-05-06 | E. I. Du Pont De Nemours & Company | Novel phenyl-substituted sulfonamides |
| US4780125A (en) * | 1982-09-01 | 1988-10-25 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
| DE3927369A1 (de) * | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
| US5064851A (en) * | 1990-07-24 | 1991-11-12 | Pfizer Inc. | 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use |
| US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| DE4344957A1 (de) * | 1993-12-30 | 1995-07-06 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen |
| CN1038679C (zh) * | 1994-12-07 | 1998-06-10 | 南开大学 | 磺酰脲类化合物及其除草用途 |
| HU226462B1 (en) * | 1995-02-17 | 2008-12-29 | Hoechst Ag | Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use |
| AU6967198A (en) * | 1997-04-10 | 1998-10-30 | Eli Lilly And Company | Diarylsulfonylureas for use in treating secretory diarrhea |
-
1997
- 1997-12-29 DK DK02020749T patent/DK1270565T3/da active
- 1997-12-29 WO PCT/IB1997/001603 patent/WO1998032733A1/en active IP Right Grant
- 1997-12-29 NZ NZ336248A patent/NZ336248A/xx unknown
- 1997-12-29 ES ES97947201T patent/ES2198598T3/es not_active Expired - Lifetime
- 1997-12-29 EA EA199900603A patent/EA001803B1/ru not_active IP Right Cessation
- 1997-12-29 PT PT97947201T patent/PT964849E/pt unknown
- 1997-12-29 AT AT02020749T patent/ATE270285T1/de not_active IP Right Cessation
- 1997-12-29 DE DE69729762T patent/DE69729762T2/de not_active Expired - Fee Related
- 1997-12-29 AU AU52340/98A patent/AU723895B2/en not_active Ceased
- 1997-12-29 KR KR1019997006786A patent/KR100324058B1/ko not_active IP Right Cessation
- 1997-12-29 ES ES02020749T patent/ES2222426T3/es not_active Expired - Lifetime
- 1997-12-29 PL PL97335052A patent/PL335052A1/xx unknown
- 1997-12-29 TR TR1999/01816T patent/TR199901816T2/xx unknown
- 1997-12-29 BR BR9714328A patent/BR9714328A/pt not_active Application Discontinuation
- 1997-12-29 JP JP51868798A patent/JP3573757B2/ja not_active Expired - Fee Related
- 1997-12-29 AT AT97947201T patent/ATE242208T1/de not_active IP Right Cessation
- 1997-12-29 DE DE69722663T patent/DE69722663T2/de not_active Expired - Fee Related
- 1997-12-29 CA CA002279186A patent/CA2279186C/en not_active Expired - Fee Related
- 1997-12-29 IL IL13085597A patent/IL130855A0/xx unknown
- 1997-12-29 CN CN97181579A patent/CN1127479C/zh not_active Expired - Fee Related
- 1997-12-29 HU HU0000567A patent/HUP0000567A3/hu unknown
- 1997-12-29 DK DK97947201T patent/DK0964849T3/da active
- 1997-12-29 EP EP97947201A patent/EP0964849B1/en not_active Expired - Lifetime
- 1997-12-29 CZ CZ19992575A patent/CZ293173B6/cs not_active IP Right Cessation
- 1997-12-29 ID IDW990764A patent/ID22223A/id unknown
- 1997-12-29 YU YU33799A patent/YU33799A/sh unknown
- 1997-12-29 SK SK982-99A patent/SK283679B6/sk unknown
- 1997-12-29 PT PT02020749T patent/PT1270565E/pt unknown
- 1997-12-29 US US09/341,782 patent/US6166064A/en not_active Expired - Fee Related
-
1998
- 1998-01-16 PA PA19988444701A patent/PA8444701A1/es unknown
- 1998-01-20 UY UY24861A patent/UY24861A1/es unknown
- 1998-01-23 PE PE1998000051A patent/PE57898A1/es not_active Application Discontinuation
- 1998-01-26 TW TW087101087A patent/TW515788B/zh not_active IP Right Cessation
- 1998-01-27 DZ DZ980017A patent/DZ2407A1/xx active
- 1998-01-27 AR ARP980100358A patent/AR011093A1/es not_active Application Discontinuation
- 1998-01-27 HR HR980045A patent/HRP980045B1/xx not_active IP Right Cessation
- 1998-01-28 TN TNTNSN98017A patent/TNSN98017A1/fr unknown
- 1998-01-28 ZA ZA9800685A patent/ZA98685B/xx unknown
- 1998-01-28 MA MA24947A patent/MA26468A1/fr unknown
- 1998-01-29 AP APAP/P/1998/001190A patent/AP929A/en active
- 1998-01-29 CO CO98004326A patent/CO4920230A1/es unknown
-
1999
- 1999-06-29 IS IS5099A patent/IS5099A/is unknown
- 1999-07-22 BG BG103597A patent/BG103597A/bg unknown
- 1999-07-23 OA OA9900165A patent/OA11079A/en unknown
- 1999-07-28 NO NO19993658A patent/NO313279B1/no not_active IP Right Cessation
-
2000
- 2000-10-31 US US09/703,142 patent/US6433009B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9714328A (pt) | da atividade de interleucina-1 | |
| MASON et al. | A permanent change in convulsive threshold in normal and brain‐damaged rats with repeated small doses of pentylenetetrazol | |
| Streck et al. | Chronic hyperhomocysteinemia provokes a memory deficit in rats in the Morris water maze task | |
| ATE256475T1 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
| EP0957903A4 (en) | PHARMACEUTICAL PREPARATIONS AND PROCEDURE | |
| CA2223776A1 (en) | Method of treatment for lung diseases using antisense oligonucleotides | |
| HUP0000558A3 (en) | Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases | |
| ES2093130T3 (es) | Forma de ciclosporin para administracion pulmonar. | |
| WO1999040197A3 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
| Brandt et al. | Sleep deprivation but not a whisker trim increases nerve growth factor within barrel cortical neurons | |
| ATE185973T1 (de) | Verwendung von humanem atrio-natriuretischem peptid zur herstellung eines medikaments zur behandlung des atemunwohlseinsyndroms bei erwachsenen | |
| DE3751036T2 (de) | Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen. | |
| Soma et al. | Effects of furosemide on the racing times of horses with exercise-induced pulmonary hemorrhage | |
| IE45054L (en) | Veterinary composition | |
| WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
| DE69004425D1 (de) | Verwendung von c-20 bis c-26-aliphatischen alkoholen zur herstellung eines arzneimittels zur behandlung viraler infektionen. | |
| KR102107808B1 (ko) | 기억력 및 인지기능 개선용 펩타이드 | |
| KR102107804B1 (ko) | 기억력 및 인지기능 개선용 펩타이드 | |
| DE59712344D1 (de) | Verwendung von peptidischen Bradykinin-Antagonisten zur Herstellung von Arzneimitteln | |
| Ksir | Rate dependent drug effects: Possible state dependency | |
| WO2001045727A3 (en) | Stabilized veterinary compositions comprising more than one antiviral agent | |
| Reid et al. | Reinforcing limbic system stimulation and sodium amytal | |
| Ananthaswamy | X-rated brains | |
| Lee et al. | Effects of DCS® hair tonic on hair growth promotion in an alopecia model of C57BL/6 mice | |
| DE69632117D1 (de) | Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36O DA LPI |